Skip to content
StockMarketAgent
Direct answer
ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $411, high $854, with mid-point at $632.
Stock analysis

ELV ELV fair value $411–$854

ELV
By StockMarketAgent.AI team· supervised by
分析日: 2026-05-13次回更新: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
株価
$381.75
▲ +250.57 (+65.64%)
公正価値
$632
$411–$854
評価
強い買い
confidence 77/100
上昇余地
+65.6%
upside to fair value
安全余裕率
$537.47
MoS level · 15%
時価総額
$82.9B
P/E fwd 13.1
英語版にフォールバックJA
翻訳中のため英語版を表示しています
このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

§1 エグゼクティブサマリー

  • Composite fair value $632 with high case $854.
  • Implied upside of 65.6% to fair value.
  • Moat 9/10 · confidence 77/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$632
Margin of safety
+39.6%
Confidence
77/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$381.75Price
Low $411.38
Mid $632.32
High $853.64

ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Scale advantages driven by a
    Scale advantages driven by a massive member base in Anthem.
  • Network effects within the integrated
    Network effects within the integrated Anthem and Carelon ecosystems.
  • Bull thesis
    Massive margin of safety with implied -6.18% perpetual growth at the current price.

§2 ベアケース

A severe scenario where elevated MLR persists due to structural shifts in medical utilization, compounded by adverse Medicare rate changes, significantly compressing operating margins below their historical norms.

このテーゼが崩れる経路

Unchecked Medical Cost Inflation

· Medium

Sustained elevated medical utilization drives MLR structurally higher, compressing operating margins permanently below historical averages.

FV impact
-35%
Trigger
12-24 Months

Severe Regulatory Reimbursement Cuts

· Low

Aggressive legislative action slashes Medicare Advantage and Medicaid reimbursement rates, effectively stunting top-line growth.

FV impact
-25%
Trigger
24-36 Months

Carelon Growth Stagnation

· Medium

Intense PBM competition limits Carelon's ability to win new external mandates, stalling the long-term margin-expansion thesis.

FV impact
-15%
Trigger
12-18 Months
監視すべき早期警戒シグナル
指標現在トリガーしきい値
Medical loss ratio sequentially rising above targeted corridors.MonitorDeterioration versus the report thesis
Regulatory announcements of tighter Medicare funding.MonitorDeterioration versus the report thesis
Stalling growth or mandate losses in the Carelon segment.MonitorDeterioration versus the report thesis
Operating margins dipping below the 5.0% normalized threshold.MonitorDeterioration versus the report thesis
Material reduction in projected share repurchase pacing.MonitorDeterioration versus the report thesis

§3 財務履歴

損益計算書 — 直近6期
項目T−0T−1T−2T−3T−4CAGR
期間2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
売上高$156.60B$171.34B$176.81B$199.13B+6.2%
売上総利益
営業利益
純利益$5.89B$5.99B$5.98B$5.66B-1.0%
EPS (希薄化後)$24.81$25.22$25.68$25.21+0.4%
EBITDA
研究開発
販管費$15.91B$17.69B+2.7%

品質スコア

OCF / 純利益
0.76×
>1 は利益の質が高いことを示す
会計品質ゲート
Fail
セクター調整後ゲート
ROIC
8.4%
投下資本利益率
セクション 3

Numbers analysis

キャッシュフロー

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

資本配分

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

個人サブスクライバー — §4以降11セクション追加

完全な分析を読む — 11セクション追加。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

カバー対象の全ティッカーの完全なレポート
24か月分の評価アーカイブ
ウォッチリストブリーフィング + 評価変更アラート
任意の言語でのPDF + DOCXエクスポート
無料トライアルを開始
いつでもキャンセル可能。
FAQ

ELV — frequently asked questions

  1. Based on our latest analysis, ELV looks meaningfully undervalued. The current price is $382 versus a composite fair-value midpoint of $632 (range $411–$854), which implies roughly 65.6% upside to the midpoint.
Related coverage

Names readers of ELV also follow

Same archetype: mature-compounder